Author:
Markham Anthony,Dhillon Sohita
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. AstraZeneca, Acerta Pharma. Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma [media release]. 1 Aug 2017. http://www.acerta-pharma.com .
2. FDA. FDA approves new treatment for adults with mantle cell lymphoma [media release]. 31 Oct 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583076.htm .
3. Acerta Pharma. Acerta Pharma announces strategic transaction with AstraZeneca [media release]. 17 Dec 2015. http://www.acerta-pharma.com .
4. Harrington BK, Gulrajani M, Covey T, et al. ACP-196 is a second generation inhibitor of bruton tyrosine kinase (BTK) with enhanced target specificity [abstract]. Blood. 2015;126(23):2908.
5. Covey T, Barf T, Gulrajani M, et al. ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients [abstract no. 2596]. Cancer Res. 2015;75(15 Suppl).
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献